Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new
incidences in 2018. An increase in incidences is an issue of concern that should be …

Cancer is a leading cause of death throughout the world, and cancer therapy remains a big
medical challenge in terms of both its therapeutic efficacy and safety. Therefore, to find out a …

Fenofibrate (FF) is a common lipid-lowering drug and a potent agonist of the peroxisome
proliferator-activated receptor alpha (PPARα). FF and several other agonists of PPARα have …

Background There are a lot of unmet needs in patients with triple-negative breast cancer
(TNBC). Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist …

Anti-neoplastic potential of calorie restriction or ligand-induced activation of peroxisome
proliferator activated receptors (PPARs) has been demonstrated in multiple studies; …

Prostate cancer is a prevalent disease that is characterized by a presumably long latency
period and a moderate propensity to metastasize. Although a range of mechanisms have …

Fenofibrate, a peroxisome proliferator‐activated receptor alpha (PPARα) agonist and lipid‐
lowering agent, has been used worldwide for treatment of hyperlipidemia. The clinical trials …

Statins and non-statin medications used for the management of dyslipidemia have been
shown to possess antitumor properties. Since the use of these drugs has steadily increased …

Metronomic agents reduce the effective doses and adverse effects of cytostatics in cancer
chemotherapy. Therefore, they can enhance the treatment efficiency of drug-resistant …

Glioblastomas are the most aggressive brain tumors for which therapeutic options are
limited. Current therapies against glioblastoma include surgical resection, followed by …